Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice

Aim. To determine lenvatinib treatment outcomes in patients with advanced unresectable hepatocellular carcinoma (uHCC) in real clinical practice.Patients and methods. A multicenter retrospective observational study included 58 patients with a confirmed uHCC diagnosis receiving lenvatinib. At baselin...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. V. Petkau, A. V. Sultanbaev, K. V. Menshikov, A. S. Antipin, M. V. Volkonsky, V. M. Filippova, Yu. V. Vasilyeva, A. A. Tarkhanov, M. R. Mukhitova, M. Zh. Murzalina, A. R. Safarova
Format:	Article
Language:	Russian
Published:	Gastro LLC 2022-12-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	liver cancer hepatocellular carcinoma hcc targeted therapy lenvatinib real clinical practice
Online Access:	https://www.gastro-j.ru/jour/article/view/723
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
by: Lingling Zhao, et al.
Published: (2025-02-01)

Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
by: Hideko Ohama, et al.
Published: (2025-01-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)

Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib
by: Naoki Fukuda, et al.
Published: (2024-04-01)

Diagnosis and treatment of hepatocellular carcinoma with pelvic metastasis expressing AFP: a case report
by: Legang Huang, et al.
Published: (2025-01-01)

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling
by: Xindong Wei, et al.
Published: (2025-01-01)

The miRNA‐mRNA Regulatory Network in Human Hepatocellular Carcinoma by Transcriptomic Analysis From GEO
by: Razieh Heidari, et al.
Published: (2025-01-01)

NSUN5 Facilitates Hepatocellular Carcinoma Progression by Increasing SMAD3 Expression
by: Hexu Han, et al.
Published: (2025-01-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta‐analytic assessment
by: Kazuo Tarao, et al.
Published: (2019-03-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

Research of <i>PNPLA3</i> I148M Gene Polymorphism in Patients with Non-Alcoholic Fatty Liver Disease, with Liver Cirrhosis and with Hepatocellular Carcinoma
by: V. V. Petkau, et al.
Published: (2023-11-01)

Dual-drug loaded chondroitin sulfate embolization beads enhance TACE therapy for HCC by integrating embolization, chemotherapy, and anti-angiogenesis
by: Jin-Xin Huang, et al.
Published: (2025-02-01)

CK19 protein expression: the best cutoff value on the prognosis and the prognosis model of hepatocellular carcinoma
by: Chenglei Yang, et al.
Published: (2025-01-01)

A hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing
by: Karina Benderski, et al.
Published: (2025-01-01)

Risk factors of development of hepatocellular carcinoma
by: V. T. Ivashkin, et al.
Published: (2009-02-01)

Metabolic reprogramming of glucose: the metabolic basis for the occurrence and development of hepatocellular carcinoma
by: Kai Wang, et al.
Published: (2025-02-01)

Liquid biopsy - a review
by: WERONIKA RUTKOWSKA-KAWALEC, et al.
Published: (2025-01-01)

Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
by: Finn RS, et al.
Published: (2025-02-01)

A bibliometric analysis of 30 years of research on transarterial radioembolization (TARE) for hepatocellular carcinoma
by: Tongyao Hu, et al.
Published: (2025-01-01)

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01)

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
by: Su H, et al.
Published: (2025-02-01)

PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma
by: San-Chi Chen, et al.
Published: (2025-02-01)

Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies
by: Elisa Monti, et al.
Published: (2025-01-01)

Long-term survival analysis of ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma conforming to the Milan criteria: primary versus recurrent HCC
by: Jing Zhang, et al.
Published: (2024-12-01)

Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel
by: V. V. Breder, et al.
Published: (2023-02-01)

Prediction of Pathologic Response in Unresectable Hepatocellular Carcinoma After Downstaging with Locoregional and Systemic Combination Therapy
by: Yang C, et al.
Published: (2025-01-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

Challenges in Diagnosing Focal Liver Lesions Using Contrast-Enhanced Ultrasound
by: Tudor Voicu Moga, et al.
Published: (2024-12-01)

DNA methylation of ACADS promotes immunogenic cell death in hepatocellular carcinoma
by: Ze Qian, et al.
Published: (2025-01-01)

Structure of Patients with Hepatocellular Cancer (Data Analysis from Two Specialised Centres)
by: M. V. Mayevskaya, et al.
Published: (2020-05-01)

Machine Learning-Based Classification and Statistical Analysis of Liver Cancer: A Comprehensive Study of Model Performance and Clinical Significance
by: Pratyush Kumar MAHARANA, et al.
Published: (2024-12-01)

Perioperative infections as a prognostic risk factor in hepatocellular carcinoma and cholangiocellular carcinoma: a comparative analysis
by: Markus S. Jördens, et al.
Published: (2025-01-01)